Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Oncol Ther ; 4(1): 129-134, 2016.
Article in English | MEDLINE | ID: mdl-28261645

ABSTRACT

Pilomatrix carcinoma is a rare cutaneous tumor derived from follicular matrix cells. It may arise de novo or from a malignant transformation of a pilomatrixoma. The latter process has been associated with impaired immune system surveillance of the host caused by UV radiation or the onset of an underlying malignant neoplasm. We report a case of a 58-year-old man presenting with a long-standing pilomatrix carcinoma on the inner right leg after 10 years of repeated curettage of the lesion, concurrent with a high-grade B-cell lymphoma on the same extremity. We describe a rare association which highlights the necessity of close follow-up of patients with long-standing malignant skin tumors.

2.
J Surg Res ; 138(1): 111-20, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17173932

ABSTRACT

BACKGROUND: Palatoplasty has the undesired side effect of impaired mid-facial growth. To avoid this problem, we propose an alternative to palatoplasty. We hypothesize that if BMP-2 is injected together with a carrier into the periosteum of the cleft palate borders, border volume will increase and connective tissue cells will be activated to produce extra bone. Once these borders supported by bone reach the midline, extraction of their covering epithelia with trypsin will permit adhesion of the underlying tissues. We investigated in vitro the ability of cleft palate connective tissue cells to produce extra bone in the presence of BMP-2 and the possibility of using trypsin to remove the epithelium covering the cleft palate borders without impairing the underlying tissues' ability to adhere. MATERIALS AND METHODS: We used the cleft palate presented by tgf-beta(3) null mice and small fragments of human cleft palate mucoperiosteum as models. Immunolabeling BMP-2-treated or untreated cultures with TUNEL and anti-osteocalcin or PCNA antibodies was performed. The epithelium of the cleft palate borders was removed with a trypsin solution, and the de-epithelialized tissues were cultured in apposition. RESULTS: BMP-2 induces differentiation toward bone on cleft palate connective tissue cells without producing cell death or proliferation. Trypsin removal of the cleft palate margins' epithelium does not impair the underlying tissues' adhesion. CONCLUSION: It is possible to generate extra bone at the cleft palate margins and to chemically eliminate their covering epithelia without damaging the underlying tissues, which allows further investigation in vivo of this new approach for cleft palate closure.


Subject(s)
Bone Morphogenetic Proteins/pharmacology , Cleft Palate/drug therapy , Palate/drug effects , Palate/pathology , Transforming Growth Factor beta/pharmacology , Animals , Bone Morphogenetic Protein 2 , Bone Morphogenetic Proteins/physiology , Cell Death/drug effects , Cell Differentiation/drug effects , Cell Division/drug effects , Cleft Palate/pathology , Connective Tissue/drug effects , Connective Tissue/physiology , Female , Male , Mice , Mice, Inbred C57BL , Osteoblasts/cytology , Palate/physiology , Pregnancy , Tissue Culture Techniques , Transforming Growth Factor beta/physiology , Trypsin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...